Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura

Haematologica

Volumn 95, Issue 9, 2010, Pages 1555-1562

  Long Zheng, X ^a   Wu, Haifeng M ^b   Shang, Dezhi ^a   Falls, Erica ^a   Skipwith, Christopher G ^a   Cataland, Spero R ^b   Bennett, Charles L ^c   Kwaan, Hau C ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

ADAMTS13; Adjunctive immunotherapy; Immunoglobulin; Thrombotic thrombocytopenic purpura

Indexed keywords

AUTOANTIBODY; CYSTEINE; IMMUNOGLOBULIN G ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PROSPECTIVE STUDY; PROTEIN DOMAIN; THROMBOCYTE COUNT; UNITED STATES;

ADAM PROTEINS; ADULT; AGED; AUTOANTIBODIES; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; YOUNG ADULT;

EID: 77956824177     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019299     Document Type: Article

References (33)

1. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855): 488-494.
2. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Path Mech Dis. 2008;3:249-77.
3. Shelat SG, Smith AG, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS- 13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707-1717.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585-1594.
5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
6. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398-403.
7. Tsai HM, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, et al. ADAMTS13- binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006;95(5):886-892.
8. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-1267.
9. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009;7(10):1703-1710.
10. Scheiflinger F, Knoebl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Non-neutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura (TTP). Blood. 2003;102(9):3241-3243.
11. Tsai HM. Is severe deficiency of ADAMTS- 13 specific for thrombotic thrombocytopenic purpura¿ Yes. J Thromb Haemost. 2003;1(4):625-631.
12. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factorcleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98(6):1765-1772.
13. Zheng XL, Sadler JE. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. In: Young NS, Gerson SL, High KA, eds. Clinical Hematology. Philadelphia: Mosby Elsevier; 2006:802-813.
14. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132(1): 66-74.
15. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232-239.
16. Zheng XL, Richard KM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043-4049.
17. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514-4519.
18. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2005;93(2):267-274.
19. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1): 60-68.
20. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
21. Niiya M, Uemura M, Zheng XW, Pollak E, Dockal M, Scheiflinger F, et al. Increased ADAMTS13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost. 2006;4(5):1063-1070.
22. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005;280(33):29428-29434.
23. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2003;103(2):607-612.
24. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxyl-terminal TSP-1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007;110(6):1887-1894.
25. Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization timeof- flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost. 2006;4(2):333-338.
26. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003;278(32): 30136-30141.
27. Cao WJ, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA. 2008;105:7416-7421.
28. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, Van Mourik JA, et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost. 2006;96(3):295-301.
29. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood. 2010;115(11): 2300-2310.
30. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA. 2006;103(50):19099-19104.
31. Jin SY, Skipwith CG, Shang D, Zheng XL. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size. J Thromb Haemost. 2009;7(10):1749-1752.
32. Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 2009;114(13):2819-2828.
33. Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem. 2009;284(45):30925-30932.